Status:
COMPLETED
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Lead Sponsor:
Washington University School of Medicine
Conditions:
Lymphatic Filariasis
Onchocerciasis
Eligibility:
All Genders
5+ years
Brief Summary
Approximately 5,200 people will participate per year. The study population will include females and males over 5 years of age who live in filariasis and onchocerciasis endemic areas. Subject selection...
Detailed Description
Lymphatic filariasis (LF) is a deforming and disabling infectious disease that causes elephantiasis and genital deformity (especially hydroceles). The infection affects some 120 million people in 81 c...
Eligibility Criteria
Inclusion
- • Study areas should be endemic for filariasis and onchocerciasis.
- • Study population have limited or no prior experience with MDA. Males and Females greater than 5 years of age.
Exclusion
- • Children less than 5 years of age.
- • Children who weigh less than 15 kg (33 lb)
Key Trial Info
Start Date :
March 1 2012
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2021
Estimated Enrollment :
21862 Patients enrolled
Trial Details
Trial ID
NCT01905436
Start Date
March 1 2012
End Date
July 1 2021
Last Update
February 11 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Liberian Institute of Biomedical Research
Charlesville, Margibi County, Liberia